Crispr Therapeutics Highlights Strategic Priorities And Anticipated 2025 Milestones
Jan 13 (Reuters) -
CRISPR Therapeutics AG ::
*CRISPR THERAPEUTICS HIGHLIGHTS STRATEGIC PRIORITIES AND ANTICIPATED 2025 MILESTONES
*TO ENGAGE REGULATORS ON CTX112 PATH FORWARD, UPDATE MID-2025
*DOSE ESCALATION FOR CTX310 AND CTX320 ONGOING, UPDATES EXPECTED H1 2025
*ONGOING LAUNCH OF CASGEVY DRIVEN BY STRONG PATIENT DEMAND
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 13-JAN-202512:00:00.877 GMT免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。